Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) insider Mark E. Dmytruk sold 34,588 shares of the stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $1.56, for a total value of $53,957.28. Following the completion of the sale, the insider now directly owns 454,549 shares of the company’s stock, valued at $709,096.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Ginkgo Bioworks Price Performance
Ginkgo Bioworks stock traded down $0.05 during mid-day trading on Friday, hitting $1.52. 16,991,994 shares of the company were exchanged, compared to its average volume of 19,453,639. The company has a quick ratio of 11.67, a current ratio of 11.71 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $2.00 and a 200 day moving average of $2.59. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $1.45 and a 1-year high of $7.37. The company has a market capitalization of $2.95 billion, a PE ratio of -0.66 and a beta of 0.68.
Ginkgo Bioworks (NYSE:DNA – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The company had revenue of $66.40 million for the quarter, compared to analyst estimates of $54.28 million. Ginkgo Bioworks had a negative return on equity of 85.90% and a negative net margin of 668.49%. As a group, sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -1.41 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on DNA shares. BTIG Research reduced their price objective on Ginkgo Bioworks to $4.00 in a research report on Thursday, November 17th. Raymond James cut their target price on Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating for the company in a research note on Tuesday, November 22nd. Morgan Stanley began coverage on Ginkgo Bioworks in a research note on Tuesday, October 4th. They issued an “equal weight” rating and a $5.00 target price for the company. Finally, Berenberg Bank began coverage on Ginkgo Bioworks in a research note on Monday, November 28th. They issued a “buy” rating and a $6.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Ginkgo Bioworks presently has an average rating of “Hold” and a consensus price target of $5.92.
Institutional Trading of Ginkgo Bioworks
Large investors have recently made changes to their positions in the business. Brown Advisory Inc. grew its holdings in shares of Ginkgo Bioworks by 199.9% during the second quarter. Brown Advisory Inc. now owns 132,549 shares of the company’s stock worth $315,000 after purchasing an additional 88,358 shares during the last quarter. Bradley Foster & Sargent Inc. CT grew its holdings in shares of Ginkgo Bioworks by 7.3% during the second quarter. Bradley Foster & Sargent Inc. CT now owns 74,390 shares of the company’s stock worth $177,000 after purchasing an additional 5,035 shares during the last quarter. Verition Fund Management LLC boosted its holdings in Ginkgo Bioworks by 28.6% in the first quarter. Verition Fund Management LLC now owns 38,581 shares of the company’s stock valued at $155,000 after acquiring an additional 8,581 shares during the last quarter. FNY Investment Advisers LLC boosted its holdings in Ginkgo Bioworks by 17.6% in the second quarter. FNY Investment Advisers LLC now owns 102,680 shares of the company’s stock valued at $244,000 after acquiring an additional 15,375 shares during the last quarter. Finally, Guild Investment Management Inc. boosted its holdings in Ginkgo Bioworks by 15.3% in the third quarter. Guild Investment Management Inc. now owns 140,835 shares of the company’s stock valued at $439,000 after acquiring an additional 18,715 shares during the last quarter. Institutional investors own 61.83% of the company’s stock.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Ginkgo Bioworks, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Ginkgo Bioworks wasn’t on the list.
While Ginkgo Bioworks currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
I have been writing professionally for over 20 years and have a deep understanding of the psychological and emotional elements that affect people. I’m an experienced ghostwriter and editor, as well as an award-winning author of five novels.